ICR | Thousands to potentially benefit from Roche treatment for sight loss

Thousands to potentially benefit from Roche treatment for sight loss

The National Institute for Health and Care Excellence (NICE) has recommended Roche’s faricimab (Vabysmo) as a treatment option for two leading forms of sight loss. Faricimab, an eye injection, is recommended for adults with wet age-related macular degeneration (AMD) or diabetic macular oedema (DMO).

The oldest independent membership-led professional body for clinical researchers across the globe.